Cipla Receives USFDA Establishment Inspection Report for Hauppauge Plant
Cipla’s wholly owned subsidiary InvaGen received the USFDA Establishment Inspection Report for its Hauppauge, New York manufacturing plant, formally closing the inspection process and reducing compliance and operational risk. The clearance supports launch momentum for North American generics, while Cipla also reported its Q1 FY27 results with higher revenue but a 39.19% YoY decline in net profit.